乏氧诱导因子的转化医学研究进展

Advances on translational research of Hypoxia-inducible factors

乏氧诱导因子(HIFs)是机体器官组织中氧分压改变后发生一系列自适应反应的重要调节因子,在血管异常增生以及肿瘤发生发展的各种病理生理变化过程中起重要作用。乏氧可显著增加肿瘤侵袭性和对放化疗的抗拒性,是肿瘤治疗的一大难题。深入开展肿瘤乏氧分子影像、乏氧相关基因表达谱的转化医学研究,指导肿瘤个体化治疗的计划制定和预后评价是肿瘤治疗发展的方向。本文拟对上述研究进展做一综述,并探讨其进一步成为转化医学研究和潜在临床应用的可能性。

Hypoxia-inducible factors（ HIFs）is an essential mediator of the adaptive response to changes of oxy-gen partial pressure in tissues or organs. It plays an important role in tumorigenesis and malignant phenotype. The hy-poxia-associated resistance to radio- and chemotherapy is a major problem in cancer therapy. With the application of PET molecular imaging and CT,MRI anatomical imaging fusion technology,the accuracy and specificity of cancer diagnosis and treatment has significantly been improved. Based on tumor hypoxia molecular imaging and hypoxia gene expression profiles,we can focus on screening and designing individualized treatment plan. In this review we discuss the latest achievements of translational medicine research of HIFs in oncology,and explore the potential to improve cancer therapeutic effect using the hypoxia molecular imaging technology and hypoxia gene expression signatures.